Clinicians including GPs should have a lower threshold for prescribing antibiotics in older people, England's chief medical ...

This week's letters to the editor cover everything from Trump brokering a Russia-Ukraine peace deal to local housing ...

Dr Ravi completed the entirety of his medical specialization in the United States — a milestone achieved by very few ...

It’s a bit of a Wild West out there when it comes to in vitro fertilization (IVF) tests and treatments. Many new tests and ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single ...

Kite, a Gilead Company , presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large ...

Zoetis Inc. ( ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation December 2, 2025 8:30 AM EST Good morning, everyone. We will now move to the Q&A portion of our ...

Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a ...

Either it was not visible due to the smog or it was this dirty grey,” says the media consultant. They moved cities so that their daughter could breathe easy. Ever since her birth, she would fall sick ...

Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation. Read here for an analysis of SMMT and AKESF.

Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced that the first patient has been dosed in the company's ...

The GOLD COPD Update 2026 provides updated guidance on case-finding, disease activity, exacerbation management.